Publication | Closed Access
Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks
46
Citations
22
References
2014
Year
Patients on BRAF inhibitor-based therapies need to continue to have regular dermatological follow-up independent of the duration of their therapy.
| Year | Citations | |
|---|---|---|
Page 1
Page 1